{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:40:30Z","timestamp":1761183630242,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jphs.2022.08.007","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T03:28:09Z","timestamp":1662089289000},"page":"191-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Appraisal of ICH E14\/S7B Q&As adopted in February 2022 using thorough QT\/QTc study data for \u03b14-integrin antagonist carotegrast methyl in Japanese healthy subjects"],"prefix":"10.1016","volume":"150","author":[{"given":"Ryuichi","family":"Kambayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Izumi-Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"ICH Harmonised Tripartite Guideline","key":"10.1016\/j.jphs.2022.08.007_bib1"},{"key":"10.1016\/j.jphs.2022.08.007_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14\/S7B Updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2022.08.007_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical\u2013clinical risk assessment to streamline QT prolongation liability determinations: a Pharma industry perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clin Pharmacol Ther"},{"year":"2022","series-title":"Clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential questions and answers","key":"10.1016\/j.jphs.2022.08.007_bib5"},{"key":"10.1016\/j.jphs.2022.08.007_bib6","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and efficacy of AJM300, an oral antagonist of \u03b14 integrin, in induction therapy for patients with active ulcerative colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jphs.2022.08.007_bib7","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2468-1253(22)00022-X","article-title":"AJM300 (carotegrast methyl), an oral antagonist of \u03b14-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"7","author":"Matsuoka","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.jphs.2022.08.007_bib8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/clpt.2014.155","article-title":"Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil","volume":"96","author":"Johannesen","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2022.08.007_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/cpt.205","article-title":"Late sodium current block for drug-induced long QT syndrome: results from a prospective clinical trial","volume":"99","author":"Johannesen","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2022.08.007_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jphs.2018.01.009","article-title":"Effects of moxifloxacin on the proarrhythmic surrogate markers in healthy Filipino subjects: exposure-response modeling using ECG data of thorough QT\/QTc study","volume":"136","author":"Matsukura","year":"2018","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2022.08.007_bib11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jcph.1534","article-title":"Effects of the fluoroquinolones moxifloxacin and levofloxacin on the QT subintervals: sex differences in ventricular repolarization","volume":"60","author":"T\u00e4ubel","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jphs.2022.08.007_bib12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1253\/circrep.CR-21-0061","article-title":"Measurement of early and late repolarization periods in addition to QT interval to help predict the torsadogenic risk of donepezil based on reverse translational animal research on its proarrhythmic potential","volume":"3","author":"Kambayashi","year":"2021","journal-title":"Circ Rep."},{"key":"10.1016\/j.jphs.2022.08.007_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12012-020-09612-3","article-title":"Cardiohemodynamic and arrhythmogenic effects of the anti-atrial fibrillatory compound vanoxerine in halothane-anesthetized dogs","volume":"21","author":"Hagiwara-Nagasawa","year":"2021","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jphs.2022.08.007_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1071\/CH9490149","article-title":"Experimental designs balanced for the estimation of residual effects of treatments","volume":"2","author":"Williams","year":"1949","journal-title":"Aust J Chem"},{"issue":"8","key":"10.1016\/j.jphs.2022.08.007_bib15","first-page":"343","article-title":"The duration of systole in an electrocardiogram in normal humans and in patients with heart disease.","volume":"2003","author":"Fridericia","year":"1920","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.jphs.2022.08.007_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jphs.2022.08.007_bib17","first-page":"45","article-title":"Correction to: scientific white paper on concentration-QTc modeling","volume":"399","author":"Garnett","year":"2018","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jphs.2022.08.007_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jcph.226","article-title":"QT\/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation","volume":"54","author":"Sugiyama","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jphs.2022.08.007_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in\u00a0vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"J\u00a0Pharmacol Toxicol Methods"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:02:32Z","timestamp":1761163352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861322000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1347861322000676"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2022.08.007","relation":{},"ISSN":["1347-8613"],"issn-type":[{"type":"print","value":"1347-8613"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Appraisal of ICH E14\/S7B Q&As adopted in February 2022 using thorough QT\/QTc study data for \u03b14-integrin antagonist carotegrast methyl in Japanese healthy subjects","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2022.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}